Verismo Therapeutics Shares Positive Preclinical Data at ASH 2025 Comparing SynKIR™-310 With Conventional CAR-T
SynKIR™-310 achieved greater tumor control at lower doses with reduced cytokines in vivo, compared to CD19-targeted CAR T cells analogous to tisagenlecleucel. Verismo Therapeutics, a clinical-stage CAR T company developing the novel KIR-CAR platform, today presented new preclinical data for SynKIR™-310, a CD19-targeting KIR-CAR T cell therapy, at the American Society of Hematology (ASH) Annual […]